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StabilityAbstract A micellar liquid chromatographic method was developed for the determination of ser-
taconazole and terconazole in bulk, dosage forms and human plasma using intersil cyano column
and mobile phase consisting of 0.1 M sodium dodecyl sulphate, 20% 1-propanol, and 0.3% trieth-
ylamine in 0.02 M ortho-phosphoric acid (pH 4) at 225 nm. Different chromatographic parameters
were studied, e.g. types of columns, pH of mobile phase, concentration of sodium dodecyl sulphate,
1-propanol, triethylamine, etc. The method was validated over the concentration ranges 8–40 and
16–80 lg/ml, for sertaconazole and terconazole, respectively. The method was sensitive with limits
of detection of 1.24 and 1.67 lg/ml for sertaconazole and terconazole in bulk, respectively. Inter
and intra-day results showed % RSD< 0.9% and 1.55% for sertaconazole and terconazole,
respectively. The result obtained by the proposed method was compared with that obtained by
the reference HPLC technique. Furthermore, the proposed method was successfully applied as a
stability-indicating method for the determination of drugs under different stressed conditions.
The method showed good selectivity, repeatability, linearity and sensitivity according to the evalu-
ation of the validation parameters.
ª 2014 Production and hosting by Elsevier B.V. on behalf of Faculty of Pharmacy, Cairo University.
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Sertaconazole (SER), (RS)-1-[2-[(7-Chloro-1-benzothiophen-
3-yl) methoxy]-2-(2,4-dichlorophenyl) ethyl]-1H-imidazole
nitrate1 (Fig. 1) is a broad spectrum antifungal agent with
excellent activity against yeasts, dermatophytes and opportu-
nistic fungi. In addition to this antifungal efﬁcacy, it has a
good safety proﬁle, sustained cutaneous retention, and low
systemic absorption, all of which make it ideal for topical
applications.2 Terconazole (TEZ) 1-[4-[[(2RS,4SR)-2-(2,4-
dichlorophenyl)-2-[(1H-1,2,4-triazol-1-yl)methyl]-1,3-dioxo-
lan-4-yl]methoxy]phenyl]-4-(1-methylethyl)piperazine1 (Fig. 1)
is a triazole antifungal agent which shows greater efﬁciency,
shorter treatment regimens, lower relapse rates and better
mycologic and clinical cure rates in comparison with other
imidazole antifungal agents in the treatment of vulvovaginal
candidiasis.3 In fact, until now, few methods have been
reported for the analysis of SER such as non-aqueous titra-
tion,4,5 spectrophotometry,6 HPLC,7,8 HPTLC6 and capillary
zone electrophoresis9 and with respect to TEZ also very
few methods have been reported for its analysis including
non-aqueous titration,4,5 spectrophotometry10 and electrokinetic chromatography.11 They are ofﬁcial in British pharma-
copeia4 and in European pharmacopeia.5
Micella liquid chromatography (MLC) is a form of
reversed phase liquid chromatography that uses an aqueous
micellar solution as the mobile phase. The use of micelles in
high performance liquid chromatography was ﬁrst introduced
by Armstrong and Henry in 1980.12 The technique is used
mainly to enhance retention and selectivity of various solutes
that would otherwise be inseparable or poorly resolved.
Micelles are composed of surfactant, or detergent, mono-
mers with a hydrophobic moiety, or tail, on the one end,
and a hydrophilic moiety, or head group, on the other. The
polar head group may be anionic, cationic, zwitterionic, or
non-ionic. The most commonly used surfactant in MLC is
the anionic sodium dodecyl sulphate (SDS). When the concen-
tration of a surfactant in solution reaches its critical micelle
concentration (CMC), it forms micelles which are aggregates
of the monomers. The CMC is different for each surfactant,
as is the number of monomers which make up the micelle,
termed the aggregation number (AN). In MLC, there are three
partition coefﬁcients which must be taken into account. The
solute will partition between the water and the stationary
Figure 1 Chemical structure of SER and TEZ.
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tionary phase, so gives a large versatility to this technique and
makes it appropriate for a wide range of solutes that can be
separated in one run.
Many of the characteristics of micelles differ from those of
bulk solvents. For example, the micelles are, by nature, spa-
tially heterogeneous with a hydrocarbon, nearly anhydrous
core and a highly solvated, polar head group. They have a high
surface-to-volume ratio due to their small size and generally
spherical shape. Their surrounding environment (pH, ionic
strength, buffer ion, presence of a co-solvent, and temperature)
has an inﬂuence on their size, shape, critical micelle concentra-
tion, aggregation number and other properties.
The main limitation in the use of MLC is the reduction in
efﬁciency (peak broadening) that is observed when purely
aqueous micellar mobile phases are used.13 Several explana-
tions for the poor efﬁciency have been theorized. Poor wetting
of the stationary phase by the micellar aqueous mobile phase,
slow mass transfer between the micelles and the stationary
phase, and poor mass transfer within the stationary phase have
all been postulated as possible causes. To enhance efﬁciency,
the most common approaches have been the addition of small
amounts of organic modiﬁers, particularly alcohol, and
increasing the column temperature. Care needs to be taken
when determining how much organic to add. Too high a con-
centration of the organic may cause the micelle to disperse, but
a generally accepted practice is to keep the volume percentage
of organic below 15–20%.
Despite the reduced efﬁciency of MLC verses RP-HPLC,
hundreds of applications have been reported using the former.
One of the prime advantages is the ability to directly inject
physiological ﬂuids. Micelles have an ability to solubilize pro-
teins which enables MLC to be useful in analysing untreated
biological ﬂuids such as plasma, serum, and urine. MLC is a
better choice than ion-exchange LC or ion-pairing LC for
the separation of charged molecules and mixtures of charged
and neutral species. Analysis of pharmaceuticals by MLC is
also gaining popularity. Another novel application of MLC
involves the separation and analysis of inorganic compounds,
mostly simple ions. This is a relatively new area for MLC.
The aim of the present work was to establish a fast, accu-
rate, reliable and validated MLC method for the determination
of SER and TEZ in bulk, pharmaceutical products and spiked
human plasma. Different chromatographic parameters were
investigated to select the optimum conditions for the separa-
tion and for applying as a stability-indicating method for their
determination under different stress conditions. The results
obtained by the proposed method were compared with those
obtained by the comparison HPLC method.4 The method
was validated according to the international conference on
harmonization guidelines (ICH).142. Experimental
2.1. Materials
SER (100.2% purity) was kindly supplied by October Pharma
Drug Company (Egypt). TEZ (99.7% purity) was kindly sup-
plied by Multiapex Pharma Drug Company (Egypt). Pharma-
ceutical formulations used were: Dermoﬁx spray solution 2%
(20 mg SER/ml) and Dermoﬁx powder 2% (20 mg SER/g)
(October Pharma Co., Egypt). Gynoconazole 80 vaginal sup-
pository (80 mg TEZ/sup.) (Multi-Apex Pharma Co., Egypt),
they were obtained from the local pharmacy.
Plasma samples were obtained from Egyptian Research and
Development Company and kept frozen until using after gen-
tle thawing.
2.2. Reagents and chemicals
All Reagents used were of analytical reagent grade and were
obtained fromMerck and Sigma. Solvents were ofHPLC grade.
High purity water was obtained by elga labwater, prima 7(UK).
Methanol, 1-propanol and acetonitrile ACN (HPLC grade)
were obtained from Sigma–Aldrich (Germany). Ortho-phos-
phoric acid (85% w/v), triethylamine (TEA) and sodium dode-
cyl sulphate (SDS, 99%) were obtained from Riedel-deHa¨en
(Sleeze, Germany). sodium hydroxide, hydrochloric acid
(32% w/v) were purchased from the El-Nasr Company, Egypt.
Hydrogen peroxide (30% w/v) was obtained from the Luna
industrial group (6th of October City, Egypt).
2.3. Equipment
Chromatographic separation was performed on a Agilent 1200
HPLC autosampler system equipped with HPLC–UV detector
1200 (Germany) and HPLC quaternary pump 1200 (Ger-
many). Analytical data were stored in a computer equipped
with Agilent software.
The pH was measured with Jenway pH meter, 3510 (Essex-
UK). The mobile phase was ﬁltered through Charles Austen
Pumps Ltd. ﬁlter, model-B100 SE (England, UK) and the solu-
tions were sonicated in ultrasonic bath Falc Treviglio (Italy).
The mobile phase and the injected solutions were ﬁltered
through 0.45 lm Millipore ﬁlters (Gelman, Germany).
2.4. Chromatographic conditions
MLC was performed on an intersil cyano column (5 lm parti-
cle size, 25 cm length 150 mm i.d.), (GL Sciences Inc., Japan)
using a micellar mobile phase consisting of 0.1 M sodium
dodecyl sulphate (SDS), 20% 1-propanol, 0.3% triethylamine
158 M. Rizk et al.(TEA) in 0.02 M ortho-phosphoric acid. The mobile phase pH
was adjusted to 4 using potassium hydroxide. The mobile
phase was ﬁltered and sonicated for 30 min before use. The
ﬂow rate was 1.0 ml/min and sample injection volumes were
20 ll at room temperature (25). The UV detector was oper-
ated at 225 nm.2.5. Standard solutions
2.5.1. Standard stock solutions of SER and TEZ (400 lg/ml)
Dissolving 20 mg of each drug in 50 ml methanol the solution
was sonicated in an ultrasonic bath for 5 min. The solutions
were found to be stable for 3 days at room temperature.3. Procedures
3.1. Construction of the calibration curve
Working solutions containing 8–40 lg/ml SER and 16–80
lg/ml TEZ were prepared by serial dilution of the standard
solution with the mobile phase. Then the solutions were son-
icated for 3 min and ﬁltered through a disposable syringe ﬁl-
ter (0.45 lm) before column injection. 20 ll aliquots of each
solution were injected in triplicate and eluted with the mobile
phase under the previously described chromatographic condi-
tions. The average peak areas were plotted versus the corre-
sponding concentrations to obtain the calibration curves.
Alternatively, the corresponding regression equations were
derived.
3.2. Analysis of SER and TEZ raw materials
Different aliquots of SER and TEZ standard solutions cover-
ing the working concentration range were transferred into a
series of volumetric ﬂasks diluted to the volume with the
mobile phase and sonicated. Triplicate 20 ll injections were
made. The percentages found were calculated from the previ-
ously constructed calibration graph or from the corresponding
regression equation.
3.3. Application of the proposed method for the determination
of pharmaceutical products
An accurate amount of each drug corresponding to 20.0 mg
SER was transferred into a 50 ml volumetric ﬂask .About
10 ml of methanol was added followed by sonication for
15 min. The solutions were completed to the volume with
methanol, mixed well and ﬁltered. Aliquots of this solution
were transferred into volumetric ﬂasks, diluted to the volume
with the mobile phase and mixed well and completed as men-
tioned before.
An accurately weighed amount of TEZ in vaginal supposi-
tory corresponding to 20.0 mg TEZ was transferred into a
100 ml beaker. About 25 ml of methanol was added followed
by sonication in an ultrasonic bath for 15 min. The solutions
were stirred for 5 min then cooled in a refrigerator. This pro-
cess was repeated twice. Then, the supernatant phase was
transferred to a 50 ml volumetric ﬂask and completed with
methanol as mentioned before.3.4. Application of the proposed method for the determination
of SER, TEZ in spiked human plasma
1 ml of human plasma was transferred into a centrifuge tube,
diluted with 1 ml of SER and TEZ, separately deprotenized
with 2 ml ACN and then vortex mixed. Final concentrations
were (10–20) lg/ml SER and (20–60) lg/ml TEZ. The solu-
tions were centrifuged at 5000 rpm for 15 min. Then, the solu-
tions were ﬁltered through a disposable syringe ﬁlter (0.45 lm)
before column injection and completed as described before.
3.5. Stress testing studies
An appropriate amount of each standard (20 lg/ml SER,
40 lg/ml TEZ) in 1 N alcoholic NaOH was left for 24 h then
the solutions were sonicated, ﬁltered through a disposable syr-
inge ﬁlter (0.45 lm), and triplicate 20 ll injections were made.
The same experiment was repeated but under different con-
ditions such as 1 N alcoholic HCl, 30%H2O2 or left in the sun-
light for 24 h.
Each experiment was carried out in triplicate and all solu-
tions were injected in triplicate. The nominal contents of each
one were calculated using the constructed calibration graph or
by the corresponding regression equation.
4. Results and discussion
The proposed MLC method represents a rapid and sensitive
stability-indicating assay method for the determination of
SER and TEZ in bulk and pharmaceutical preparations.
Moreover, it was extended to investigate the inherent stability
of SER, TEZ under different stress conditions. By virtue of its
high sensitivity, the proposed method was applied for the
determination of SER, TEZ in human plasma without need
for tedious sample pre-treatment steps.
4.1. Optimization of chromatographic performance and system
suitability
Different parameters affecting the chromatographic perfor-
mance of SER and TEZ were carefully studied in order to
achieve the most suitable chromatographic system. The results
of the optimization study can be presented as follows:
4.1.1. Choice of appropriate detection wavelength
The absorption spectrum of SER, TEZ in the micellar mobile
phase exhibits maximum absorption at 210 nm. But most com-
pounds especially endogenous compounds in plasma show
absorption at this wavelength, so we tried variable wavelengths
and found that 225 nm is the most suitable wavelength to SER
and TEZ which gives reasonable sensitivity. The 3-D ﬁgures of
SER and TEZ are shown in Fig. 2.
4.1.2. Choice of column
To investigate the chromatographic performance, different
columns had been tried, these include reversed-phase C8,
reversed-phase C18, two bonded phase cyano and bonded
phase phenyl columns.
Experimental trials revealed that the Intersil cyano column
(5 lm particle size, 25 cm length 150 mm i.d.), GL Sciences
Figure 2 3-D ﬁgure showing kmax of (A) SER, (B) TEZ.
Figure 3 Representative chromatogram using the proposed method for the determination of 40 lg/ml SER, 50 lg/ml TEZ.
Determination of sertaconazole and terconazole 159Inc., Japan, was the most suitable one giving narrower sym-
metric peaks and the highest number of theoretical plates
within a reasonable analysis time. Chromatogram of SER
and TEZ on the intersil cyano column is shown in Fig. 3.
4.1.3. Mobile phase composition
To achieve the best chromatographic conditions, the mobile
phase composition was optimized to provide sufﬁcient selectiv-
ity and sensitivity in a short separation time. The studied vari-
ables included; the pH and the ﬂow rate of the mobile phase,
concentration of SDS, organic modiﬁer and TEA.
The pH of the mobile phase was studied over the range of
2.5–4.5. Mobile phases with pH values ranged from 3.5 to 4.0
provided suitable peak symmetry and better peak shape.
Increasing the pH of the mobile phase more than 4.0 caused
an increase in the retention time of SER and TEZ. Finally,
pH 4.0 was selected as the optimum pH value for the mobile
phase in this study yielding the highest number of theoretical
plates with good peak shape and lowest peak tailing.
The effect of ﬂow rate of the mobile phase on the retention
of SER and TEZ was investigated over the range of 1.0–2.0 ml/
min. Flow rate of 1.0 ml/min was chosen since it provides a
better peak shape within a reasonable time. Also different con-
centrations of SDS, organic modiﬁer and TEA were studied.
After optimization of these variables, best peak shape, with
lowest peak tailing was achieved and well-deﬁned peaks and
good sensitivity within a reasonable analytical run time were
obtained under the selected chromatographic conditions as
shown in Fig. 3.
4.2. Method validation
The validity of the proposed method was assessed by studying
the following parameters in accordance to ICH guideline14: lin-earity, range, LOD, LOQ, accuracy, precision, selectivity, sam-
ple solution stability, mobile phase stability, system suitability
and robustness.
4.2.1. Linearity and range
Under optimum chromatographic conditions, linear relation-
ship was established by plotting average peak areas against
SER and TEZ concentrations (lg/ml), respectively as illus-
trated in Fig. 4.
The calibration graphs were found to be rectilinear over the
concentration ranges of 8–40, 16–80 (lg/ml) for SER and
TEZ, respectively with good correlation coefﬁcient (r) and rel-
ative standard deviation (RSD) according to the following
regression equations. The results are illustrated in Table 1.
These data proved the linearity of the calibration graph.
Y ¼ 86:50X 63:82ðR2 ¼ 0:999Þ For SER
Y ¼ 40:86X 32:89ðR2 ¼ 0:999Þ For TEZ4.2.2. Limit of detection (LOD) and limit of quantiﬁcation
(LOQ)
LOD (the lowest concentration that can be determined) and
LOQ (the lowest concentration of a substance that can be
quantiﬁed with acceptable precision and accuracy) for SER
and TEZ were calculated according to ICH Q2 (R1) recom-
mendation.14 The results are shown in Table 1.
4.2.3. Accuracy
To prove the accuracy of the proposed method, the results of
the assay of SER and TEZ in pure form by the proposed MLC
method were compared with those obtained using a compari-
son HPLC method.4
Figure 4 Calibration curve using the proposed MLC method for
(A) SER, (B) TEZ.
Table 1 Performance data using the proposed method for
determination of SER and TEZ in pure form.
Parameter SER TEZ
Concentration range (lg/ml) 8–40 16–80
LOD (lg/ml) 1.24 1.67
LOQ (lg/ml) 3.78 5.06
r 0.9995 0.9997
Slope 86.508 40.9
Intercept 63.826 32.89
Standard deviation of the residuals 32.66 20.725
% RSD (SD X 100/X`) 1.03 2.37
% Error (% RSD/
p
n) 0.27 0.56
Table 2 Accuracy and precision of the proposed MLC
method for the determination of (A) SER and (B) TEZ in
pure form.
Parameter Proposed method Comparison
method4
Conc. taken
(lg/ml)
Conc. found
(lg/ml)
% Found* % Found*
(A)
8 8.1 101.3 102.4
12 12.3 102.5 103.1
16 16.2 101.3 102.8
20 20.4 102.00 103.4
40 39.9 99.8 100.2
X ± SD 101.4 ± 1.2 102.4 ± 1.3
t 1.4(1.9)**
F 1.6(6.4)**
(B)
16 16.7 104.4 103.2
24 24.1 100.4 101.2
32 32.2 100.6 99.5
40 40.0 100.0 99.8
48 47.7 99.4 98.2
80 80.2 100.3 99.7
X ± SD 100.9 ± 1.8 100.4 ± 1.9
t 0.6 (1.8)**
F 1.1 (5.1)**
* Each result is the average of three separate determinations.
** Values between parentheses are the tabulated t and F values at
n= 18 and p= 0.05.15
Table 3 Precision data of the proposed method for the
determination of (A) SER in dosage forms and (B) TEZ in its
dosage form.
% Found + SD % RSD % Error
(A)
Intra-day precision
Dermoﬁx solution 104.7 ± 0.9 0.9 0.3
Dermoﬁx powder 102.5 ± 0.6 0.6 0.2
Inter-day precision
Dermoﬁx solution 104.6 ± 0.6 0.6 0.1
Dermoﬁx powder 101.8 ± 0.5 0.5 0.1
(B)
Intra-day precision
Gynoconazole suppository 102.9 ± 1.6 1.5 0.5
Inter-day precision
Gynoconazole suppository 103.1 ± 0.9 0.8 0.2
160 M. Rizk et al.Statistical comparison using t-test and F-test revealed that
there were no signiﬁcant differences between the performance
of the two methods regarding the accuracy and precision,
respectively as shown in Table 2. For SER, The comparison
HPLC method involved the use of a mobile phase consisting
of ACN: Sodium dihydrogen phosphate (37:63, v/v) and stain-
less steel column packed with nitrile silica gel with detection at
220 nm.4
For TEZ, The comparison HPLC method involved the use
of a mobile phase as gradient elution consisting of 3.4 g/l tet-
rabutyl ammonium hydrogen sulphate and ACN using C18
column at 220 nm.44.2.4. Precision
Intra-day precision was achieved by six replicate determina-
tions of 20 lg/ml SER and 40 lg/ml TEZ, respectively in dif-
ferent dosage forms on three successive times in the same day.
Inter-day precision was performed as intra-day precision
but on three successive days. Small values of % error and %
RSD revealed the precision of the proposed method. The
results are illustrated in Table 3.
4.2.5. Selectivity
The speciﬁcity of the proposed MLC method was established
by its ability to determine the cited substance in commercial
Table 4 System suitability test parameters for the developed
MLC method for SER and TEZ.
Parameter SER TEZ
No of theoretical plates, N 1151 1300
Capacity factor, K0 1.83 1.85
Selectivity factor, a 2.13 2.4
Resolution factor, Rs 4.12 4.3
Figure 6 Representative chromatogram showing TEZ in Gyno-
conazole suppository (40 lg/ml).
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common excipients did not show any interfering peaks at
retention times of the drug.
Furthermore, to evaluate the speciﬁcity of the method to
determine SER and TEZ in human plasma, blank plasma
was diluted with the micellar mobile phase and injected under
the recommended chromatographic conditions. A peak
appears at the retention time of the two drugs. So, slight mod-
iﬁcations were made on the mobile phase to overcome this
problem. In a 1 L volumetric ﬂask, 350 ml deionized water,
0.1 M SDS, 20% 1-propanol, and 0.3% TEA were added
and completed to the mark using 0.02 M ortho-phosphoric
acid. The mobile phase pH was adjusted using potassium
hydroxide to 3.5 at ﬂow rate 1.5 ml/min. Then, no endogenous
interference was observed at the retention times of SER and
TEZ, proving the speciﬁcity of the method.
Forced Degradation studies were also performed accord-
ingly to evaluate the validity of the method. The results
obtained indicated that the proposed MLC method is selective
and able to determine SER and TEZ.
4.2.6. Sample solution stability and mobile phase stability
Evaluation of the stability of SER and TEZ in standard solu-
tion and in their dosage forms solutions was achieved by quan-
tiﬁcation of SER and TEZ on three successive days and
compared to freshly prepared solutions. Similarly, the stability
of the mobile phase was checked. No signiﬁcant changes were
observed in drugs solutions or mobile phase responses, relative
to freshly prepared ones. The results obtained in both cases
proved that the sample solution and mobile phase used during
the assay were stable up to 3 days.
4.2.7. System suitability test
Evaluation of SST parameters was performed during the
development and optimization of the method. Moreover, toFigure 5 Representative chromatogram shascertain the effectiveness of the ﬁnal operating system, it
was subjected to suitability testing. The test was performed
by injecting the standard sample in triplicate and the parame-
ters were calculated as reported by USP.16 SST parameters
include capacity factor (k0), selectivity factor (a), resolution
factor (Rs), and column efﬁciency (number of theoretical
plates, N). The ﬁnal SST parameters under the optimum chro-
matographic conditions are abridged in Table 4.
4.2.8. Robustness
To assess the robustness of the proposed MLC method, chro-
matographic conditions were deliberately altered. The tested
variables included; concentration of 1-propanol (20 ± 0.5%
v/v), strength of ortho-phosphoric acid (0.02 M± 0.005),
and concentration of TEA (0.3 ± 0.01%).The efﬁciency of
the separation of SER and TEZ was not affected by all the var-
ied chromatographic conditions indicating the reliability of the
proposed method.
4.3. Applications
4.3.1. Application of the proposed method for the determination
of SER in dosage forms
The developed MLC method was applied successfully for the
assay of SER and TEZ in their dosage forms as shown in
Figs. 5 and 6, respectively.
The results obtained by the developed MLC method were
statistically compared with those of the comparison HPLC
method4 using the t-test and F-test. In both tests, the calcu-owing SER in dosage forms (20 lg/ml).
Table 5 Application of the proposed and comparison method for the determination of (A) SER in its dosage forms and (B) TEZ in its
dosage form.
Pharmaceutical preparation Proposed method Comparison method4
Conc.Taken Conc. Found % Found* % Found*
(A)
Dermoﬁx solution 16 15.7 98.1 99.2
20 19.3 96.5 97.4
24 23.1 96.3 97.0
X ± SD 97.0 ± 1.0 97.9 ± 1.2
t 1.0 (2.1)**
F 1.4(19.0)**
Dermoﬁx powder 8 7.8 97.5 98.4
20 19.6 98.0 97.7
40 39.9 99.8 100.5
X ± SD 98.4 ± 1.2 98.9 ± 1.5
t 0.4 (2.1)**
F 1.5 (19.0)**
(B)
Gynoconazole suppository (80 mg TEZ /Supp) 16 17.5 109.4 108.2
40 42.6 106.5 106.9
48 51.9 108.1 107.5
X ± SD 108.0 ± 1.5 107.6 ± 1.9
t 0.3 (2.1)**
F 1.8 (19.0)**
* Each result is the average of three separate determinations.
** Values between parentheses are the tabulated t and F values at p= 0.05.15
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conﬁdence level, which indicated that there were no signiﬁcant
differences between the developed and comparison methods
regarding accuracy and precision, respectively as shown in
Table 5.
4.3.2. Application of the proposed method to the determination
of SER in spiked human plasma
MLC allows biological samples to be analysed without prior
tedious pre-treatment for plasma protein precipitation or elim-
ination of other interfering substances, thus considerably
reducing the cost and analysis time. The proposed MLC
method was successfully applied for the determination of
SER and TEZ in spiked human plasma showing satisfactory
results. The assay results using the proposed method are sum-
marized in Tables 6 and 7. Fig. 7 shows representative chro-
matograms for blank and spiked plasma samples.Table 6 Assay results for the determination of SER in spiked
human plasma using the proposed method.
Parameter Conc. added
(lg/ml)
Conc. found
(lg/ml)
% Recovery
Spiked plasma 10 10.5 105.0
12.5 12.4 99.2
20 20.5 102.5
X ± SD 102.2 ± 2.9
% RSD 2.8
% Error 0.94.4. Results of stress testing studies
The proposed method was applied to assess the inherent stabil-
ity of SER and TEZ under different conditions such as: Alka-
line, acidic, oxidative and photolytic conditions. The studied
compounds were found to be highly labile to alkaline hydroly-
sis which resulted in about 68–100% degradation of SER dos-
age forms while TEZ in Gynoconazole vaginal suppository
was nearly diminished. Acidic degradation of SER using 1 N
HCl for 24 h. resulted in about 50% degradation in the pow-
der, while no effect was noticed in the spray solution (About
5% decrease). TEZ in its dosage form showed a slight decrease
in peak area about 10%. After exposure of SER and TEZ in
their dosage forms to oxidative degradation by 30% H2O2
for 24 h, deterioration of the peak was observed in Dermoﬁx
powder and Dermoﬁx solution, while no effect appears on
TEZ in Gynoconazole suppository. Exposing SER to sunlightTable 7 Assay results for the determination of TEZ in spiked
human plasma using the proposed method.
Parameter Conc. added
(lg/ml)
Conc. found
(lg/ml)
% Recovery
Spiked plasma 25 24.9 99.4
50 50.5 101.0
62.5 67.2 107.5
x ± SD 102.6 ± 4.3
% RSD 4.2
% Error 1.4
Figure 7 Representative chromatograms showing (A) blank plasma and (B) plasma sample spiked with SER or TEZ.
Determination of sertaconazole and terconazole 163resulted into about 65% degradation while, no effect appeared
on TEZ in its suppositories which revealed its stability. SER
and TEZ did not exhibit any degradation peaks that could
interfere with the proposed MLC method.
5. Conclusion
The proposed MLC method represents a new rapid and sensi-
tive stability-indicating assay method for the determination of
SER and TEZ, respectively in bulk and commercial dosage
forms. The proposed method was applied for the determina-
tion of SER and TEZ in human plasma with no need for
tedious sample pre-treatment steps. In addition, it was
extended to investigate the inherent stability of SER and
TEZ under different stress conditions.
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None.
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